Clinical trials: Advanced Malignant Tumors Lymphomas
Advanced Cancer
A Study of WXFL10030390 in Patients With Advanced Solid Tumors or Lymphoma
WXFL10030390 (WX390) is a novel oral small molecular that inhibits phosphoinositide-3 kinase (PI3K) and mammalian target of rapamycin (mTOR) and has demonstrated potent inhibitory effects on multiple human tumor xenografts.
- Trial name
- NCT03730142
- Testing
- WXFL10030390
- Where
- China
- Volunteers
- 82 people
- Sponsor
- Shanghai Jiatan Pharmatech Co., Ltd
Lung Cancer, Lymphoma
Vandetanib and Bevacizumab in Treating Patients With Advanced Solid Tumors or Lymphoma
RATIONALE: Vandetanib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as bevacizumab, can block cancer growth in different ways.
- Conditions
- Lung Cancer, Lymphoma, Lymphoproliferative Disorder, Small Intestine Cancer
- Trial name
- NCT00734890
- Testing
- bevacizumab, vandetanib, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- National Institutes of Health Clinical Center (CC)
Locally Advanced Cutaneous Squamous Cell Carcinoma of the Head and Neck, Melanoma Neoplasms
Evaluation of Skin Tests in Biotherapy Allergies
Biotherapies are biological (extracted from an organism or living tissue) or biotechnological drugs used in the treatment of multiple conditions, such as autoimmune inflammatory diseases, cancers, and hematologic diseases.
- Conditions
- Locally Advanced Cutaneous Squamous Cell Carcinoma of the Head and Neck, Melanoma Neoplasms, Small Cell Bronchial Carcinomas, Bronchial Carcinoma
- Trial name
- ETCABIO (NCT06971848)
- Testing
- Drug skin tests (investigating hypersensitivity to a biotherapy)
- Where
- France
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- University Hospital, Angers
Cancer
Irinotecan and Capecitabine in Treating Patients With Solid Tumors
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00003867
- Testing
- capecitabine, irinotecan hydrochloride
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Montefiore Medical Center
Advanced Solid Tumors, Relapsed/Refractory B-cell Lymphoma
Study Evaluating ISM8207 in Participants With Advanced Solid Tumors and Relapsed/Refractory B-Cell Lymphoma
The goal of this clinical trial is to study ISM8207 in participants with advanced solid tumors and relapsed/refractory B-cell lymphoma.
- Trial name
- NCT06445517
- Testing
- ISM8207
- Where
- 4 sites in China
- Volunteers
- 60 people
- Sponsor
- InSilico Medicine Hong Kong Limited
Malignant Neoplasm, Carcinoma, Merkel Cell
A Study of Pembrolizumab in Japanese Pediatric Participants With Solid Tumors or Lymphomas and Japanese Adult Participants With Merkel Cell Carcinoma (MK-3475-G21/KEYNOTE-G21)
Researchers are looking for new ways to treat people with solid tumors, lymphomas (blood cancers), and a certain type of skin cancer.
- Conditions
- Malignant Neoplasm, Carcinoma, Merkel Cell, Lymphoma
- Trial name
- NCT07302347
- Testing
- Pembrolizumab
- Where
- 7 sites in Japan
- Volunteers
- 20 people
- Sponsor
- Merck Sharp & Dohme LLC
Lymphoma, Metastatic Malignant Solid Neoplasm
Testing the Combination of Copanlisib, Nivolumab and Ipilimumab in Patients With Advanced Cancer and Lymphoma
This phase Ib trial studies the side effects and best dose of copanlisib and nivolumab and side effects of copanlisib given together with nivolumab and ipilimumab in treating patients with solid tumors that may have spread from…
- Conditions
- Lymphoma, Metastatic Malignant Solid Neoplasm, Recurrent Malignant Solid Neoplasm, Unresectable Malignant Solid Neoplasm
- Trial name
- NCT03502733
- Testing
- Biopsy Procedure, Biospecimen Collection, Computed Tomography
- Where
- 3 sites in United States
- Volunteers
- 64 people
- Sponsor
- National Cancer Institute (NCI)
Tumors, Hodgkins Disease
Study of Vinorelbine Liposomes Injection for Advanced Solid Tumors, Non-Hodgkin's Lymphoma or Hodgkin's Disease
This Phase 1 study will determine the safety, tolerability, and pharmacokinetics of vinorelbine liposomes injection (VLI) in patients with advanced solid tumors, non-Hodgkin's lymphoma, or Hodgkin's disease.
- Conditions
- Tumors, Hodgkins Disease, Non-Hodgkins Lymphoma
- Trial name
- NCT00364676
- Testing
- VLI
- Where
- 3 sites in United States, Canada
- Volunteers
- 67 people
- Sponsor
- Spectrum Pharmaceuticals, Inc
Solid Tumor, Lymphoma
Study of TJ011133 in Participants With Relapsed/Refractory Advanced Solid Tumors and Lymphoma
The purpose of this study is to assess the safety and tolerability of TJ011133 in participants with solid tumors and lymphoma.
- Trial name
- NCT03934814
- Testing
- TJ011133, Pembrolizumab, Rituximab
- Where
- 21 sites in United States, China
- Volunteers
- 98 people
- Sponsor
- I-Mab Biopharma US Limited
Advanced Malignant Solid Neoplasm, Caregiver
Frequency of Cachexia in Ambulatory Cancer Patients and Psychological Burden in Patients and Their Primary Caregivers
This trial studies the frequency of cachexia in ambulatory cancer patients and the psychological burden in patients and their primary caregivers who are referred to an outpatient supportive care clinic.
- Conditions
- Advanced Malignant Solid Neoplasm, Caregiver, Metastatic Malignant Solid Neoplasm, Recurrent Leukemia
- Trial name
- NCT04090619
- Testing
- Questionnaire Administration
- Where
- United States
- Volunteers
- 192 people, healthy volunteers welcome
- Sponsor
- M.D. Anderson Cancer Center
Advanced Solid Tumor, Refractory Hodgkin Lymphoma
An Engineered Sirpα Fused to Anti-Pd-L1 And Tgf-β Fusion Protein (HCB301) in Subjects With Selected Advanced Tumors
The purpose of this study is to find out whether IV injection of HCB301 is an effective treatment for different types of advanced solid tumors and relapsed and refractory classical Hodgkin lymphomas and what side effects…
- Trial name
- NCT06487624
- Testing
- HCB301
- Where
- 7 sites in United States, China and 1 more
- Volunteers
- 50 people
- Sponsor
- FBD Biologics Limited
Multiple Myeloma, Diffuse Large B-Cell Lymphoma
Study to Assess Safety, Pharmacokinetics, and Efficacy of Oral CC-223 for Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma or Multiple Myeloma
The main purpose of this first human study with CC-223 is to assess the safety and action of a new class of experimental drug (dual mTOR inhibitors) in patients with advanced tumors unresponsive to standard therapies and to…
- Conditions
- Multiple Myeloma, Diffuse Large B-Cell Lymphoma, Glioblastoma Multiforme, Hepatocellular Carcinoma
- Trial name
- NCT01177397
- Testing
- CC-223
- Where
- 16 sites in United States, France and 2 more
- Volunteers
- 226 people
- Sponsor
- Celgene
Advanced Tumor, Lymphoma
To Evaluate a Phase I/II Clinical Study of XNW5004 Tablets in Patients With Relapsed/Refractory Advanced Tumors
Patients with advanced tumors diagnosed histologically or cytologically at the study center who were refractory to standard therapy or had relapsed received XNW5004 tablets
- Trial name
- NCT06558513
- Testing
- XNW5004 tablets
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Evopoint Biosciences Inc.
Carcinoma, Renal Cell, Advanced, Lymphoma, Mantle-Cell
Registry For Temsirolimus, Sunitinib, And Axitinib Treated Patients With Metastatic Renal Cell Carcinoma (mRCC), Mantle Cell Lymphoma (MCL), And Gastro-Intestinal Stroma Tumor (GIST) [STAR-TOR]
The purpose of this registry is to obtain a general view as regards efficacy, tolerability and safety issues of the Torisel®, Sutent®, and/or Inlyta® therapies in patients with advanced renal cell carcinoma, recurrent /…
- Conditions
- Carcinoma, Renal Cell, Advanced, Lymphoma, Mantle-Cell, Gastrointestinal Stroma Tumors
- Trial name
- STAR-TOR (NCT00700258)
- Testing
- Temsirolimus, Sunitinib, Axitinib
- Where
- 77 sites in Germany
- Volunteers
- 1,520 people
- Sponsor
- Pfizer
Advanced Solid Tumor, Relapsed/Refractory Lymphoma
A Study of OVV-01 Injection in Combination With IBR900 Cell Injection in Patients With Advanced Malignant Tumors
This is a prospective, multi-center, open-label, single-arm, investigator-initiated clinical trial to evaluate the safety and efficacy of oncolytic virus injection (OVV-01) in combination with trained immunity NK (tiNK) cell…
- Trial name
- NCT05271279
- Testing
- OVV-01 Injection+IBR900 Cell Injection
- Where
- China
- Volunteers
- 2 people
- Sponsor
- Beijing Boren Hospital
Diffuse Large B Cell Lymphoma, Primary Mediastinal Lymphoma
Open-Label, Multi-Center, Two-Part, Ph1 Study to Characterize the PKs of an Intravenous Micro-Dose of [14C]-Tazemetostat (EPZ 6438) and the ADME of an Oral [14C]-Labeled Dose of Tazemetostat in Subjects With B-Cell Lymphomas or Adv Solid Tumors
This is a Phase 1, open-label, two-part study designed to characterize the PK of an IV dose of approximately 12 µg tazemetostat that contains approximately 500 nCi of [14C] tazemetostat and the ADME of an oral dose of 800 mg…
- Conditions
- Diffuse Large B Cell Lymphoma, Primary Mediastinal Lymphoma, Mantle-Cell Lymphoma, Follicular Lymphoma
- Trial name
- NCT03010982
- Testing
- Tazemetostat and [14C] Tazemetostat
- Where
- 2 sites in United Kingdom
- Volunteers
- 3 people
- Sponsor
- Epizyme, Inc.
Solid Tumor, Adult, Head and Neck Cancer
PROCLAIM-CX-2029: A Trial to Find Safe and Active Doses of an Investigational Drug CX-2029 for Patients With Solid Tumors or DLBCL
The purpose of this first-in-human study of CX-2029 is to characterize the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and antitumor activity of CX-2029 in adult subjects with metastatic or locally advanced…
- Conditions
- Solid Tumor, Adult, Head and Neck Cancer, Non Small Cell Lung Cancer, Diffuse Large B Cell Lymphoma
- Trial name
- NCT03543813
- Testing
- CX-2029
- Where
- 25 sites in United States, South Korea and 2 more
- Volunteers
- 133 people
- Sponsor
- CytomX Therapeutics
Acute Myeloid Leukemia, Myelodysplasia
Pilot Study of Umbilical Cord Blood Transplantation in Adult Patient With Advanced Hematopoietic Malignancies
This is a pilot study designed to evaluate the safety and feasibility of performing umbilical cord blood transplants in adults with high-risk hematopoietic malignancies. A novel myeloablative preparative regimen will be used.
- Conditions
- Acute Myeloid Leukemia, Myelodysplasia, Acute Lymphoblastic Leukemia, Chronic Myelogenous Leukemia
- Trial name
- NCT00514722
- Testing
- umbilical cord stem cells
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- University of California, San Francisco
Leukemia, Lymphoma
Megadose CD34 Selected Progenitor Cells for Transplantation in Patients With Advanced Hematological Malignant Diseases
Donor: This clinical study will evaluate the feasibility of a purified CD34 peripheral blood progenitor cell (PBPC) transplants in patients with hematological malignancies.
- Trial name
- NCT00038857
- Testing
- Megadose of CD34 Selected Progenitor Cells, Melphalan, Thiotepa
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- M.D. Anderson Cancer Center
Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma
3-AP and Gemcitabine in Treating Patients With Advanced Solid Tumors or Lymphoma
This phase I trial is studying the best dose of 3-AP and the side effects of giving 3-AP together with gemcitabine in treating patients with advanced solid tumors or lymphoma.
- Conditions
- Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Intraocular Lymphoma
- Trial name
- NCT00293345
- Testing
- gemcitabine hydrochloride, triapine
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- National Cancer Institute (NCI)